Chlorhexidine 0.2% Mouthrinse — Competitive Intelligence Brief

Chlorhexidine 0.2% Mouthrinse (Chlorhexidine 0.2% Mouthrinse) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimicrobial agent / Antiseptic. Area: Oral Health / Dentistry.

marketed Antimicrobial agent / Antiseptic Bacterial cell membrane and proteins Oral Health / Dentistry Small molecule

Target snapshot

Chlorhexidine 0.2% Mouthrinse (Chlorhexidine 0.2% Mouthrinse) — University of Oslo. Chlorhexidine is a broad-spectrum antimicrobial agent that disrupts bacterial cell membranes and denatures proteins, reducing oral microbial load.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Chlorhexidine 0.2% Mouthrinse TARGET	Chlorhexidine 0.2% Mouthrinse	University of Oslo	marketed	Antimicrobial agent / Antiseptic	Bacterial cell membrane and proteins
Adapalene + benzoyl peroxide samples	Adapalene + benzoyl peroxide samples	Wake Forest University	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)
Chlorhexidine rinse	Chlorhexidine rinse	Universidade Estadual Paulista Júlio de Mesquita Filho	marketed	Antimicrobial oral rinse	Bacterial cell membrane and proteins
Adapalene/Benzoyl Peroxide Facial Gel	Adapalene/Benzoyl Peroxide Facial Gel	Bausch Health Americas, Inc.	marketed	Retinoid and peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)
A (Chloraprep)	A (Chloraprep)	Instituto de Investigacion Sanitaria La Fe	marketed	Topical antiseptic	Bacterial cell membrane and proteins
Adapalene/Benzoyl Peroxide Gel 0.3-2.5%	Adapalene/Benzoyl Peroxide Gel 0.3-2.5%	Derm Research, PLLC	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)
Adapalene/benzoyl peroxide gel, 0.1%/2.5%	Adapalene/benzoyl peroxide gel, 0.1%/2.5%	Galderma R&D	marketed	Retinoid + peroxide combination	Retinoic acid receptors (adapalene); bacterial cell membrane and proteins (benzoyl peroxide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimicrobial agent / Antiseptic class)

1. Universidad de Guanajuato · 2 drugs in this class
2. University of Oslo · 2 drugs in this class
3. Johns Hopkins University · 1 drug in this class
4. The Cooper Health System · 1 drug in this class
5. Universidade Federal do Ceara · 1 drug in this class
6. University of Milan · 1 drug in this class
7. University of Pavia · 1 drug in this class
8. University of Pennsylvania · 1 drug in this class
9. University of Santiago de Compostela · 1 drug in this class
10. HaEmek Medical Center, Israel · 1 drug in this class